Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs American States Water Company (AWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs American States Water Company — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.81 (market cap $39.89B), while American States Water Company trades at $85.05 (market cap $3.31B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 12.1× American States Water Company's market cap, and American States Water Company pays a 2.39% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | AWR | |
|---|---|---|
Market Cap | $39.89B | $3.31B |
Sector | Health | Utilities |
52-Week High | $491.22 | $84.76 |
52-Week Low | $278.09 | $70.10 |
Enterprise Value | $38.15B | $4.22B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
American States Water (AWR) trades at $84.51, up 0.78% today, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company reported solid 2025 results with $658M revenue and $130M net income, maintaining a robust 19.66% net margin. Recent news highlights its inclusion in TIME's America's Best Companies 2026 list and a completed $200M equity offering, reinforcing its stable utility model and 71-year dividend growth streak.
AWR offers defensive appeal with reliable dividends and infrastructure investments, but faces execution risks from regulatory approvals and interest rate sensitivity. Analyst consensus is mixed with 20% buy ratings, reflecting cautious optimism amid recent earnings misses. The stock's premium valuation (P/E 24.64) requires sustained growth to justify upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About American States Water Company
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →
